DENGUE

PREVENTION
• Shara Gacute
• Karylle Cortes
• Kyla Cornal
 DENGUE VIRUS (DENV)

May also be called as :

Breakbone fever
Dandy Fever
Dengue Hemorrhagic Fever
Dengue Shock Syndrome
 Is the cause of dengue fever.
Has increased dramatically within the
last 20 years.
Became the worst mosquito-borne
human pathogens.
Can be found in tropical and subtropical
climates worldwide.
Mostly in urban and semi-urban areas.
Estimates to have infected 390 million
people each year.
The incubation period is 3-14 days, while
the period of the illness is 3-7 days.

SIGNS AND SYMPTOMS

 Severe headache
 Retro-orbital pain
 Muscle, Joint, and Bone pain
 Macular or Maculopapular rash
 Minor hemorrhagic manifestations
 Severe Disease
Some people suffer from more severe forms
of dengue, such as dengue hemorrhagic fever.
Among the possible causes are cross-
serotypic immune response , through a
mechanism known as antibody-dependent
enhancement, which happens when a person
who has been previously infected with
dengue gets infected for the second, third, or
fourth time. The previous antibodies to the
Vaccine Research
Only one vaccine for dengue is
currently approved in 11 countries
(Mexico, Philippines, Indonesia, Brazil,
El Salvador, Costa Rica, Paraguay,
Guatemala, Peru, Thailand and
Singapore)
Several vaccines are under
development by private and public
researchers.
The World Health Organization
recommends an Integrated Vector
Control program consisting of five
elements.

1. Advocacy, social mobilization and legislation to ensure

that public health bodies and communities are
strengthened;
2. Collaboration between the health and other sectors
(public and private);
3. An integrated approach to disease control to maximize
use of resources;
4. Evidence-based decision making to ensure any